Related Experiment Video
Updated: Jan 9, 2026

09:08
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
7.1K
A Prognostic Nomogram Based on an Immunogenic Cell Death and Endoplasmic Reticulum Stress-Related Gene Signature for
Xiaojuan Lu1, Lixia Zhu1, Xuegang Zhang1
1Department of Gynecology, Kunshan First People's Hospital, Kunshan, Jiangsu, 215300, People's Republic of China.
International Journal of Women'S Health
|December 3, 2025
Summary
A new seven-gene signature predicting ovarian cancer survival was developed. This immunogenic cell death and endoplasmic reticulum stress signature aids in risk stratification and personalized treatment planning for ovarian cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Gene signatures are more powerful prognostic tools than single-gene biomarkers.
- Ovarian cancer (OC) prognosis and survival prediction require improved methods.
Purpose of the Study:
- To develop a nomogram for predicting overall survival (OS) in ovarian cancer patients.
- The nomogram is based on a gene signature related to immunogenic cell death (ICD) and endoplasmic reticulum (ER) stress.
Main Methods:
- Identified ICD- and ER stress-related genes from public datasets.
- Screened candidate genes using differential expression and survival analyses.
- Developed a prognostic risk score using Cox and LASSO regression, validated with Kaplan-Meier and multivariate analyses.
Main Results:
- A seven-gene signature for ICD and ER stress was established, generating a prognostic risk score.
- Low-risk patients demonstrated significantly longer OS than high-risk patients.
- The signature served as an independent prognostic factor for OS, with good predictive performance (AUCs 0.60-0.67).
Conclusions:
- A clinically applicable nomogram integrating a seven-gene ICD/ER stress signature was developed for individualized OC patient survival prediction.
- This nomogram can assist clinicians in risk stratification and personalized treatment strategies for ovarian cancer.

